Mayzent and Multiple sclerosis - a phase IV clinical study of FDA data
Summary:
Multiple sclerosis is reported as a side effect among people who take Mayzent (siponimod fumaric acid), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Metformin, and have Secondary progressive multiple sclerosis.
The phase IV clinical study analyzes which people have Multiple sclerosis when taking Mayzent. It is created by eHealthMe based on reports of 10,267 people who have side effects when taking Mayzent from the FDA, and is updated regularly.
What is Mayzent?
Mayzent has active ingredients of siponimod fumaric acid. eHealthMe is studying from 10,269 Mayzent users. Check the latest studies of Mayzent.
What is Multiple sclerosis?
Multiple sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath) is found to be associated with 1,085 drugs and 1,365 conditions by eHealthMe. Check the latest studies of Multiple sclerosis.
10,267 people reported to have side effects when taking Mayzent.
Among them, 521 people (5.07%) have Multiple sclerosis.
Among these 521 people:
How long have people been on Mayzent when they have Multiple sclerosis? *
What is the gender of people who have Multiple sclerosis when taking Mayzent? *
What is the age of people who have Multiple sclerosis when taking Mayzent? *
What are other drugs people take besides Mayzent? *
What are other side effects people have besides Multiple sclerosis? *
What are the existing conditions these people have? *
* Approximation only. Some reports may have incomplete information.
Do you take Mayzent and have Multiple sclerosis?
- Check whether Multiple sclerosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Mayzent:
- Mayzent (10,269 reports)
Multiple sclerosis treatments and more:
- Multiple sclerosis (799,637 reports)
How severe was Multiple sclerosis and when was it recovered:
Expand to all the drugs that have ingredients of siponimod fumaric acid:
Sub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Mayzent:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Multiple sclerosis:
- Multiple sclerosis (1,085 drugs)
Browse all the conditions that are associated with Multiple sclerosis:
- Multiple sclerosis (1,365 conditions)
Related publications that referenced our studies
- Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
- Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
- Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
- Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
How the study uses the data?
The study uses data from the FDA. It is based on siponimod fumaric acid (the active ingredients of Mayzent) and Mayzent (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Remicade and Asthenia for Men aged 60+ - 2 seconds ago
- Remicade and Muscle Fatigue for Men aged 60+ - 2 seconds ago
- Remicade and Muscular Weakness for Men aged 60+ - 3 seconds ago
- Remicade and Lack Of Strength, Muscle Weakness, Weakness for Men aged 60+ - 3 seconds ago
- Remicade and Muscle Weakness for Men aged 60+ - 3 seconds ago
- Remicade and Lack Of Strength for Men aged 60+ - 4 seconds ago
- Remicade and Weakness for Men aged 60+ - 4 seconds ago
- Could Tricor cause Hyperlipidaemia? - 4 seconds ago
- Could Amlodipine cause Basal Ganglia Haemorrhage? - 15 seconds ago
- Joint Stiffness and drugs of ingredients of fluorouracil - 19 seconds ago